The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer
{{output}}
Introduction: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NSCLC rema... ...
